Report cover image

Asthma and COPD Drugs Market by Diseases (Asthma and COPD) and Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, and Ot

Publisher Allied Market Research
Published Feb 22, 2022
Length 120 Pages
SKU # ALMR17117595

Description

Asthma and COPD Drugs Market by Diseases (Asthma and COPD) and Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, and Others.): Global Opportunity Analysis and Industry Forecast, 2021––2030

The asthma and COPD drugs market was valued at $32988.7 million in 2020 and is projected to reach $52049.54 million by 2030, registering a CAGR of 4.64%% from 2021 to 2030.

Asthma is a respiratory disorder, in which there is narrowing of bronchi that leads to difficulty in breathing. Asthma patients may suffer with shortness of breath, chest tightness or pain, and wheezing sound while exhaling. Chronic Obstructive Pulmonary Diseases (COPD) is a group of respiratory disorders, which mainly includes emphysema and chronic bronchitis.

Asthma and COPD can be diagnosed by performing X-ray imaging, nitric oxide test, and sputum examination test. Asthma and COPD have broncho constricton as common symptoms and can be treated with corticosteroids, anticholinergic drugs, and long acting beta agonists. Patients that have asthma may suffer with sudden broncho constriction, generally known as asthmatic attack. Asthmatic attack can be treated with bronchodilators. In emergency conditions, broncho dilators are delivered with specially designed pump for quick relief.

The increase in prevalence of asthma globally drives the growth of asthma and COPD drugs market. For instance, according to report of Global Asthma Network published on 2020, asthma kills around 1000 people every day and affects as many as 339 million people globally. In addition, increase in awareness about the respiratory diseases in people propels the growth of asthma and COPD drugs market. The R&D in the treatment of the asthma by manufacturers and researchers also contributes in the growth of market. Furthermore, initiatives taken by respective governments to treat and improve the lifestyle of asthma & COPD patients boosts market growth. The rise in number of hospitals and well-developed healthcare infrastructure further contributes in market growth.

In addition, increase in the tobacco smoking habits in people and he rise in air pollution contribute in the growth of the asthma and COPD drugs market. However, the high cost of treatment and lack of awareness in people about asthma & COPD are expected to limit the growth of market.

The asthma and COPD drugs market is segmented on the basis of diseases, medication class, and region. By diseases, the market is divided into asthma and COPD. By medication class, the market is divided into combination drugs, inhaled corticosteroids (ics), short acting beta agonists (saba), long acting beta agonists (laba), leukotriene antagonists (lta), anticholinergics and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Abbott Laboratories, AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC., Hoffmann-La Roche Ltd, Novartis AG, Organon, Sanofi, Teva Pharmaceutical Industries Ltd., and Vectura Group plc.

KEY BENEFITS FOR STAKEHOLDERS

The report provides an in-depth analysis of the global asthma and COPD drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global asthma and COPD drugs market growth.

KEY MARKET SEGMENTS


By Diseases
Asthma

COPD


By Medication class

Combination drugs
Short Acting Beta Agonists (SABA)
Long Acting Beta Agonists (LABA)
Leukotriene Antagonists (LTA)
Anticholinergics
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific
Japan
China
Australia
India
South Korea
Rest of Asia Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS

Abbott Laboratories
AstraZeneca
Boehringer Ingelheim International GmbH
GlaxoSmithKline PLC.
Hoffmann-La Roche Ltd
Novartis AG
Organon
Sanofi
Teva Pharmaceutical Industries Ltd.
Vectura Group plc

Table of Contents

120 Pages
CHAPTER 1:INTRODUCTION
1.1.Report Description
1.2.Key Market Segments
1.3.Key Benefits
1.4.Research Methodology
1.4.1.Primary Research
1.4.2.Secondary Research
1.4.3.Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market Definition and Scope
3.2.Key Findings
3.2.1.Top Investment Pockets
3.2.2.Top Winning Strategies
3.3.Porter's Five Forces Analysis
3.3.1.Bargaining Power of Suppliers
3.3.2.Threat of New Entrants
3.3.3.Threat of Substitutes
3.3.4.Competitive Rivalry
3.3.5.Bargaining Power among Buyers
3.4.Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5.Market Dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis
CHAPTER 4:ASTHMA AND COPD DRUGS MARKET, BY DISEASES
4.1.Market Overview
4.1.1Market Size and Forecast, By Diseases
4.2. Asthma
4.2.1.Key Market Trends, Growth Factors and Opportunities
4.2.2.Market Size and Forecast, By Region
4.2.3.Market Share Analysis, By Country
4.3.COPD
4.3.1.Key Market Trends, Growth Factors and Opportunities
4.3.2.Market Size and Forecast, By Region
4.3.3.Market Share Analysis, By Country
CHAPTER 5:ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS
5.1.Market Overview
5.1.1Market Size and Forecast, By Medication Class
5.2.Combination Drugs
5.2.1.Key Market Trends, Growth Factors and Opportunities
5.2.2.Market Size and Forecast, By Region
5.2.3.Market Share Analysis, By Country
5.3.Short Acting Beta Agonists (SABA)
5.3.1.Key Market Trends, Growth Factors and Opportunities
5.3.2.Market Size and Forecast, By Region
5.3.3.Market Share Analysis, By Country
5.4.Long Acting Beta Agonists (LABA)
5.4.1.Key Market Trends, Growth Factors and Opportunities
5.4.2.Market Size and Forecast, By Region
5.4.3.Market Share Analysis, By Country
5.5.Leukotriene Antagonists (LTA)
5.5.1.Key Market Trends, Growth Factors and Opportunities
5.5.2.Market Size and Forecast, By Region
5.5.3.Market Share Analysis, By Country
5.6.Anticholinergics
5.6.1.Key Market Trends, Growth Factors and Opportunities
5.6.2.Market Size and Forecast, By Region
5.6.3.Market Share Analysis, By Country
5.7. Others
5.7.1.Key Market Trends, Growth Factors and Opportunities
5.7.2.Market Size and Forecast, By Region
5.7.3.Market Share Analysis, By Country
CHAPTER 6:ASTHMA AND COPD DRUGS MARKET, BY REGION
6.1.Market Overview
6.1.1Market Size and Forecast, By Region
6.2.LAMEA
6.2.1.Key Market Trends and Opportunities
6.2.2.Market Size and Forecast, By Diseases
6.2.3.Market Size and Forecast, By Medication Class
6.2.4.Market Size and Forecast, By Country
6.2.5.BrazilAsthma And Copd Drugs Market
6.2.5.1.Market Size and Forecast, By Diseases
6.2.5.2.Market Size and Forecast, By Medication Class
6.2.6.South Africa,Asthma And Copd Drugs Market
6.2.6.1.Market Size and Forecast, By Diseases
6.2.6.2.Market Size and Forecast, By Medication Class
6.2.7.Saudi ArabiaAsthma And Copd Drugs Market
6.2.7.1.Market Size and Forecast, By Diseases
6.2.7.2.Market Size and Forecast, By Medication Class
6.2.8.Rest of LAMEAAsthma And Copd Drugs Market
6.2.8.1.Market Size and Forecast, By Diseases
6.2.8.2.Market Size and Forecast, By Medication Class
6.3.North America
6.3.1.Key Market Trends and Opportunities
6.3.2.Market Size and Forecast, By Diseases
6.3.3.Market Size and Forecast, By Medication Class
6.3.4.Market Size and Forecast, By Country
6.3.5.United StatesAsthma And Copd Drugs Market
6.3.5.1.Market Size and Forecast, By Diseases
6.3.5.2.Market Size and Forecast, By Medication Class
6.3.6.CanadaAsthma And Copd Drugs Market
6.3.6.1.Market Size and Forecast, By Diseases
6.3.6.2.Market Size and Forecast, By Medication Class
6.3.7.MexicoAsthma And Copd Drugs Market
6.3.7.1.Market Size and Forecast, By Diseases
6.3.7.2.Market Size and Forecast, By Medication Class
6.4.Europe
6.4.1.Key Market Trends and Opportunities
6.4.2.Market Size and Forecast, By Diseases
6.4.3.Market Size and Forecast, By Medication Class
6.4.4.Market Size and Forecast, By Country
6.4.5.FranceAsthma And Copd Drugs Market
6.4.5.1.Market Size and Forecast, By Diseases
6.4.5.2.Market Size and Forecast, By Medication Class
6.4.6.GermanyAsthma And Copd Drugs Market
6.4.6.1.Market Size and Forecast, By Diseases
6.4.6.2.Market Size and Forecast, By Medication Class
6.4.7.ItalyAsthma And Copd Drugs Market
6.4.7.1.Market Size and Forecast, By Diseases
6.4.7.2.Market Size and Forecast, By Medication Class
6.4.8.SpainAsthma And Copd Drugs Market
6.4.8.1.Market Size and Forecast, By Diseases
6.4.8.2.Market Size and Forecast, By Medication Class
6.4.9.U.KAsthma And Copd Drugs Market
6.4.9.1.Market Size and Forecast, By Diseases
6.4.9.2.Market Size and Forecast, By Medication Class
6.4.10.Rest Of EuropeAsthma And Copd Drugs Market
6.4.10.1.Market Size and Forecast, By Diseases
6.4.10.2.Market Size and Forecast, By Medication Class
6.5.Asia-Pacific
6.5.1.Key Market Trends and Opportunities
6.5.2.Market Size and Forecast, By Diseases
6.5.3.Market Size and Forecast, By Medication Class
6.5.4.Market Size and Forecast, By Country
6.5.5.ChinaAsthma And Copd Drugs Market
6.5.5.1.Market Size and Forecast, By Diseases
6.5.5.2.Market Size and Forecast, By Medication Class
6.5.6.Japan Asthma And Copd Drugs Market
6.5.6.1.Market Size and Forecast, By Diseases
6.5.6.2.Market Size and Forecast, By Medication Class
6.5.7.India Asthma And Copd Drugs Market
6.5.7.1.Market Size and Forecast, By Diseases
6.5.7.2.Market Size and Forecast, By Medication Class
6.5.8.South KoreaAsthma And Copd Drugs Market
6.5.8.1.Market Size and Forecast, By Diseases
6.5.8.2.Market Size and Forecast, By Medication Class
6.5.9.Australia Asthma And Copd Drugs Market
6.5.9.1.Market Size and Forecast, By Diseases
6.5.9.2.Market Size and Forecast, By Medication Class
6.5.10.Rest of Asia Pacific Asthma And Copd Drugs Market
6.5.10.1.Market Size and Forecast, By Diseases
6.5.10.2.Market Size and Forecast, By Medication Class
CHAPTER 7:COMPANY PROFILES
7.1. Abbott Laboratories
7.1.1.Company Overview
7.1.2.Key Executives
7.1.3.Company snapshot
7.1.4.Operating business segments
7.1.5.Product portfolio
7.1.6.Business Performance
7.1.7.Key Strategic Moves and Developments
7.2. AstraZeneca Plc
7.2.1.Company Overview
7.2.2.Key Executives
7.2.3.Company snapshot
7.2.4.Operating business segments
7.2.5.Product portfolio
7.2.6.Business Performance
7.2.7.Key Strategic Moves and Developments
7.3. Boehringer Ingelheim International GmbH
7.3.1.Company Overview
7.3.2.Key Executives
7.3.3.Company snapshot
7.3.4.Operating business segments
7.3.5.Product portfolio
7.3.6.Business Performance
7.3.7.Key Strategic Moves and Developments
7.4. Glaxosmithkline Plc
7.4.1.Company Overview
7.4.2.Key Executives
7.4.3.Company snapshot
7.4.4.Operating business segments
7.4.5.Product portfolio
7.4.6.Business Performance
7.4.7.Key Strategic Moves and Developments
7.5. Hoffmann-La Roche Ltd
7.5.1.Company Overview
7.5.2.Key Executives
7.5.3.Company snapshot
7.5.4.Operating business segments
7.5.5.Product portfolio
7.5.6.Business Performance
7.5.7.Key Strategic Moves and Developments
7.6. Novartis AG
7.6.1.Company Overview
7.6.2.Key Executives
7.6.3.Company snapshot
7.6.4.Operating business segments
7.6.5.Product portfolio
7.6.6.Business Performance
7.6.7.Key Strategic Moves and Developments
7.7. Organon
7.7.1.Company Overview
7.7.2.Key Executives
7.7.3.Company snapshot
7.7.4.Operating business segments
7.7.5.Product portfolio
7.7.6.Business Performance
7.7.7.Key Strategic Moves and Developments
7.8. Sanofi
7.8.1.Company Overview
7.8.2.Key Executives
7.8.3.Company snapshot
7.8.4.Operating business segments
7.8.5.Product portfolio
7.8.6.Business Performance
7.8.7.Key Strategic Moves and Developments
7.9. Teva Pharmaceutical Industries Ltd
7.9.1.Company Overview
7.9.2.Key Executives
7.9.3.Company snapshot
7.9.4.Operating business segments
7.9.5.Product portfolio
7.9.6.Business Performance
7.9.7.Key Strategic Moves and Developments
7.10. Vectura Group Plc
7.10.1.Company Overview
7.10.2.Key Executives
7.10.3.Company snapshot
7.10.4.Operating business segments
7.10.5.Product portfolio
7.10.6.Business Performance
7.10.7.Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1.GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASES, 2020-2030 ($MILLION)
TABLE 2.GLOBAL ASTHMA AND COPD DRUGS MARKET FOR ASTHMA, BY REGION, 2020-2030 ($MILLION)
TABLE 3.GLOBAL ASTHMA AND COPD DRUGS MARKET FOR COPD, BY REGION, 2020-2030 ($MILLION)
TABLE 4.GLOBAL ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 5.GLOBAL ASTHMA AND COPD DRUGS MARKET FOR COMBINATION DRUGS, BY REGION, 2020-2030 ($MILLION)
TABLE 6.GLOBAL ASTHMA AND COPD DRUGS MARKET FOR SHORT ACTING BETA AGONISTS (SABA), BY REGION, 2020-2030 ($MILLION)
TABLE 7.GLOBAL ASTHMA AND COPD DRUGS MARKET FOR LONG ACTING BETA AGONISTS (LABA), BY REGION, 2020-2030 ($MILLION)
TABLE 8.GLOBAL ASTHMA AND COPD DRUGS MARKET FOR LEUKOTRIENE ANTAGONISTS (LTA), BY REGION, 2020-2030 ($MILLION)
TABLE 9.GLOBAL ASTHMA AND COPD DRUGS MARKET FOR ANTICHOLINERGICS, BY REGION, 2020-2030 ($MILLION)
TABLE 10.GLOBAL ASTHMA AND COPD DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 11.GLOBAL ASTHMA AND COPD DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 12.LAMEA ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 13.LAMEA ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 14.BRAZIL ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 15.BRAZIL ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 16.SOUTH AFRICA, ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 17.SOUTH AFRICA, ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 18.SAUDI ARABIA ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 19.SAUDI ARABIA ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 20.REST OF LAMEA ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 21.REST OF LAMEA ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 22.NORTH AMERICA ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 23.NORTH AMERICA ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 24.UNITED STATES ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 25.UNITED STATES ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 26.CANADA ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 27.CANADA ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 28.MEXICO ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 29.MEXICO ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 30.EUROPE ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 31.EUROPE ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 32.FRANCE ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 33.FRANCE ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 34.GERMANY ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 35.GERMANY ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 36.ITALY ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 37.ITALY ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 38.SPAIN ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 39.SPAIN ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 40.UNITED KINGDOM ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 41.UNITED KINGDOM ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 42.REST OF EUROPE ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 43.REST OF EUROPE ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 44.ASIA-PACIFIC ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 45.ASIA-PACIFIC ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 46.CHINA ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 47.CHINA ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 48.JAPAN ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 49.JAPAN ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 50.INDIA ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 51.INDIA ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 52.SOUTH KOREA ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 53.SOUTH KOREA ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 54.AUSTRALIA ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 55.AUSTRALIA ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 56.REST OF ASIA PACIFIC ASTHMA AND COPD DRUGS, BY DISEASES, 2020-2030 ($MILLION)
TABLE 57.REST OF ASIA PACIFIC ASTHMA AND COPD DRUGS, BY MEDICATION CLASS, 2020-2030 ($MILLION)
TABLE 58.ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 59.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 60.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 61.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 62.ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 63.ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 64.ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 65.ASTRAZENECA PLC: OPERATING SEGMENTS
TABLE 66.ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 67.ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 68.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
TABLE 69.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 70.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OPERATING SEGMENTS
TABLE 71.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 72.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 73.GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 74.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 75.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 76.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 77.GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78.HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
TABLE 79.HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 80.HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 81.HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 82.HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 83.NOVARTIS AG: KEY EXECUTIVES
TABLE 84.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 85.NOVARTIS AG: OPERATING SEGMENTS
TABLE 86.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 87.NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 88.ORGANON: KEY EXECUTIVES
TABLE 89.ORGANON: COMPANY SNAPSHOT
TABLE 90.ORGANON: OPERATING SEGMENTS
TABLE 91.ORGANON: PRODUCT PORTFOLIO
TABLE 92.ORGANON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93.SANOFI: KEY EXECUTIVES
TABLE 94.SANOFI: COMPANY SNAPSHOT
TABLE 95.SANOFI: OPERATING SEGMENTS
TABLE 96.SANOFI: PRODUCT PORTFOLIO
TABLE 97.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
TABLE 99.TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 100.TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS
TABLE 101.TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 102.TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 103.VECTURA GROUP PLC: KEY EXECUTIVES
TABLE 104.VECTURA GROUP PLC: COMPANY SNAPSHOT
TABLE 105.VECTURA GROUP PLC: OPERATING SEGMENTS
TABLE 106.VECTURA GROUP PLC: PRODUCT PORTFOLIO
TABLE 107.VECTURA GROUP PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1.GLOBAL ASTHMA AND COPD DRUGS MARKET SEGMENTATION
FIGURE 2.GLOBAL ASTHMA AND COPD DRUGS MARKET
FIGURE 3.SEGMENTATION ASTHMA AND COPD DRUGS MARKET
FIGURE 4.TOP INVESTMENT POCKET IN ASTHMA AND COPD DRUGS MARKET
FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.LOW THREAT OF SUBSTITUTION
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.TOP PLAYER POSITIONING, 2020
FIGURE 14.MARKET SHARE ANALYSIS, 2020
FIGURE 15.RESTRAINTS AND DRIVERS: ASTHMA AND COPD DRUGS MARKET
FIGURE 16.ASTHMA AND COPD DRUGS MARKET SEGMENTATION, BY DISEASES
FIGURE 17.ASTHMA AND COPD DRUGS MARKET FOR ASTHMA, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.ASTHMA AND COPD DRUGS MARKET FOR COPD, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 19.ASTHMA AND COPD DRUGS MARKET SEGMENTATION, BY MEDICATION CLASS
FIGURE 20.ASTHMA AND COPD DRUGS MARKET FOR COMBINATION DRUGS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 21.ASTHMA AND COPD DRUGS MARKET FOR SHORT ACTING BETA AGONISTS (SABA), BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 22.ASTHMA AND COPD DRUGS MARKET FOR LONG ACTING BETA AGONISTS (LABA), BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 23.ASTHMA AND COPD DRUGS MARKET FOR LEUKOTRIENE ANTAGONISTS (LTA), BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 24.ASTHMA AND COPD DRUGS MARKET FOR ANTICHOLINERGICS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 25.ASTHMA AND COPD DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 26.ABBOTT LABORATORIES: NET SALES, 2018-2020 ($MILLION)
FIGURE 27.ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 28.ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 29.ASTRAZENECA PLC: NET SALES, 2018-2020 ($MILLION)
FIGURE 30.ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2018-2020 ($MILLION)
FIGURE 33.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.GLAXOSMITHKLINE PLC: NET SALES, 2018-2020 ($MILLION)
FIGURE 36.GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.HOFFMANN-LA ROCHE LTD: NET SALES, 2018-2020 ($MILLION)
FIGURE 39.HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40.HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 41.NOVARTIS AG: NET SALES, 2018-2020 ($MILLION)
FIGURE 42.NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43.NOVARTIS AG: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 44.ORGANON: NET SALES, 2018-2020 ($MILLION)
FIGURE 45.ORGANON: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 46.ORGANON: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 47.SANOFI: NET SALES, 2018-2020 ($MILLION)
FIGURE 48.SANOFI: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 49.SANOFI: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 50.TEVA PHARMACEUTICAL INDUSTRIES LTD: NET SALES, 2018-2020 ($MILLION)
FIGURE 51.TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 52.TEVA PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 53.VECTURA GROUP PLC: NET SALES, 2018-2020 ($MILLION)
FIGURE 54.VECTURA GROUP PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 55.VECTURA GROUP PLC: REVENUE SHARE, BY REGION, 2020 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us